Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

BTAI - BioXcel Therapeutics, Inc. Financial... | Finranks

Home

/

BTAI

B

BioXcel Therapeutics, Inc. (BTAI)

NCM – Real Time Price. Currency in USD

1.03

+0.10 (10.74%)

Market open: Aug 12, 2026, 10:16 AM EDT

0.93

+0.00 (0.01%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Total Assets

Total Liabilities

Stockholders Equity

Total Debt

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

642K

2M

1M

375K

Cost of goods sold

-464K

-2M

-2M

-347K

Gross Profit

178K

-186K

-198K

28K

Operating expenses (excl. COGS)

-50M

-63M

-166M

-158M

Operating Income

-50M

-63M

-166M

-158M

Non-operating income, total

-20M

4M

-13M

-8M

Pretax income

-70M

-60M

-179M

-166M

Equity in earnings

0

0

0

0

Taxes

0

0

0

167K

Non-controlling/minority interest

0

0

0

0

After tax other income/expense

0

0

0

0

Net income before discontinued operations

-70M

-60M

-179M

-166M

Discontinued operations

0

0

0

0

Net income

-70M

-60M

-179M

-166M

Dilution adjustment

0

0

0

0

Preferred dividends

0

0

0

0

Name

2025

2024

2023

2022

Total assets

48M+24.0%

38M-48.0%

74M-64.2%

206M

Total current assets

45M

37M

72M

203M

Total non-current assets

3M

944K

2M

3M

Total liabilities

143M+8.8%

131M+0.9%

130M+0.9%

129M

Total current liabilities

54M

22M

27M

33M

Total non-current liabilities

89M

109M

103M

96M

Total equity

-95M

-93M

-57M

77M

Total liabilities & shareholders' equities

48M

38M

74M

206M

Total debt

119M+16.0%

103M+1.5%

101M+7.6%

94M

Name

2025

2024

2023

2022

Cash from operating activities

-58M

-72M

-155M

-135M

Cash from investing activities

0

0

-20K

-139K

Cash from financing activities

57M

37M

27M

96M

Free cash flow

-58M+20.0%

-72M+53.5%

-155M-14.4%

-135M